HLA-C*0303 | B2M

Produktanfrage

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Relatlimab	ONO-4482; BMS-986016	Phase 3 Clinical	Bristol-Myers Squibb Company	Leukemia, Myeloid, Acute; Uveal melanoma; Nasopharyngeal Carcinoma; Urinary Bladder Diseases; Sarcoma; Brain Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gliosarcoma; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Urogenital Neoplasms; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Large intestine neoplasm; Male Urogenital Diseases; Adenocarcinoma; Glioblastoma; Solid tumours; Female Urogenital Diseases and Pregnancy Complications; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Hodgkin Disease; Hematologic Neoplasms; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Medullary; Urologic Diseases; Female Urogenital Diseases; Urinary Bladder Neoplasms; Multiple Myeloma; Chordoma	Details
Eftilagimod alpha	IMP-321; hLAG-3Ig; CD-223; EDP-202; EOC-202	Phase 3 Clinical	Immutep, Prima Biomed Ltd	Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Sarcoma; Breast Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Melanoma	Details
Fianlimab	REGN-3767	Phase 3 Clinical		Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma	Details
Tebotelimab	PD-1 X LAG-3; MGD-013	Phase 3 Clinical	Macrogenics Inc	Triple Negative Breast Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Endometrial Neoplasms; Cholangiocarcinoma; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms	Details
Mavezelimab/Pembrolizumab	MK-4280A; MK-4820A	Phase 3 Clinical	Msd Ireland (Carlow) Merck Sharp & Dohme Corp, MSD R&D（China）Co Ltd	Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Neoplasm Metastasis	Details
SHR-1802	SHR-1802	Phase 2 Clinical		Solid tumours; Neoplasms	Details
Tobemstomig	RO-7247669	Phase 2 Clinical	F. Hoffmann-La Roche Ltd	Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma	Details
Tuparstobart	INCAGN-02385; INCAGN-2385	Phase 2 Clinical	Agenus Inc, Incyte Corp	Head and Neck Neoplasms; Lymphoma, B-Cell; Carcinoma, Merkel Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Melanoma	Details
LBL-007	LBL-007	Phase 2 Clinical	Leads Biolabs Inc	Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma	Details
Negalstobart	IBI-110	Phase 2 Clinical	Innovent Biologics(Suzhou) Co Ltd	Hematologic Neoplasms; Skin Melanoma; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung	Details
Mavezelimab	MK-4280	Phase 2 Clinical	Merck Sharp & Dohme Corp	Lymphoma, B-Cell; Carcinoma, Renal Cell; Hodgkin Disease; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	Details
Ieramilimab	IMP-701; LAG-525	Phase 2 Clinical	Immutep	Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Esophageal adenocarcinoma; Melanoma; Persistent Fetal Circulation Syndrome	Details
Miptenalimab	BI-754111	Phase 2 Clinical	C.H. Boehringer Sohn Ag & Co. Kg	Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis	Details
FS 118	FS-118	Phase 2 Clinical	Merck Serono, F-Star	Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis	Details
HLX-26	HLX-26	Phase 2 Clinical		Solid tumours; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung	Details
GLS-012	GLS-012	Phase 2 Clinical	Harbin Gloria Pharmaceuticals Co Ltd	Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung	Details
EMB-02	EMB-02	Phase 2 Clinical	Shanghai Epimab Biotherapeutics, Inc	Solid tumours	Details
DNV-3	DNV3; DNV-3	Phase 2 Clinical	Zhejiang Shimai Pharmaceutical Co Ltd	Solid tumours; Neoplasms; Skin Neoplasms; Lymphoma	Details
KL-A289	KL-A289	Phase 1 Clinical	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Solid tumours	Details
Bavunalimab	XmAb-22841; XmAb-841	Phase 1 Clinical	Xencor Inc	Cholangiocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck	Details
Sym-022	Sym-022; Sym022; S95017	Phase 1 Clinical	Symphogen A/S	Solid tumours; Lymphoma; Neoplasm Metastasis	Details
MIL-98	MIL-98	Phase 1 Clinical	Beijing Mabworks Biotech Co Ltd	Solid tumours; Breast Neoplasms; Lymphoma; Melanoma	Details
ABL-501	ABL-501	Phase 1 Clinical	Abl Bio Inc	Solid tumours	Details
ZGGS-15	ZGGS15; ZGGS-15	Phase 1 Clinical	Suzhou Zelgen Biopharmaceuticals Co Ltd	Solid tumours	Details
INCA-32459	INCA-32459	Phase 1 Clinical	Incyte Corp, Merus Nv	Neoplasms	Details
AK-129	AK-129	Phase 1 Clinical	Zhongshan Akeso Biopharma Co Ltd	Neoplasms; Hodgkin Disease	Details
IBI-323(Innovent Biologics)	IBI-323	Phase 1 Clinical	Innovent Biologics(Suzhou) Co Ltd	Solid tumours; Neoplasms	Details
Encelimab	TSR-033; TSR 033; TSR033; GSK-4074386	Phase 1 Clinical	Anaptysbio Inc	Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Nivolumab/Relatlimab	BMS-986213; BMS-936558/BMS-986016	Approved	Bristol-Myers Squibb Company	OPDUALAG	United States	Melanoma	Bristol-Myers Squibb Company	2022-03-18	Solid tumours; Skin Melanoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Merkel Cell; Colorectal Neoplasms; Melanoma	Details